Articles

Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026

Minghui Pharmaceutical and Qilu Pharmaceutical Co. have announced updated clinical data from their Phase I/II study of MHB088C (QLC5508) in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) at the 2026 ASCO Annual Meeting. The findings demonstrated encouraging anti-tumor activity and durable disease control.

Hypertrophic Cardiomyopathy After Braunwald

The Pulse of ACC commemorates the indelible legacy of Dr. Eugene Braunwald, widely recognized as the father of modern cardiology, particularly for his foundational work in hypertrophic cardiomyopathy. The article also serves as a call for community feedback to guide the future direction of cardiovascular medicine.

Illumina APAC Strategy Under Nilesh Shah

Nilesh Shah's appointment as Head of Region, APAC for Illumina signals a strategic focus on expanding the company's footprint in the dynamic Asian market. This move is poised to influence competitive dynamics within the genomics and diagnostics sectors across the region.

Women Clinical Trials Gap: Asia Opportunity

For decades, medical research has disproportionately focused on male physiology, leading to a significant gap in understanding and treating diseases in women. As Asia's healthcare landscape evolves, it has a critical opportunity to lead in addressing this historical oversight.

Childhood Vaccine Schedule EO: Pharma Impact

An executive order has been signed, initiating an overhaul of the childhood vaccine schedule. This development prompts a critical review of its potential impact on pharmaceutical manufacturers and public health strategies.

HER2 Biology: Enhertu Expands Cancer Reach

Understanding HER2 biology is crucial for developing next-generation cancer therapies. This article delves into how advancements in HER2 research are shaping new treatment paradigms and creating opportunities for pharmaceutical innovation.

Xocova FDA Nod: COVID Post-Exposure Prevention

Shionogi's COVID-19 antiviral, Xocova, has secured FDA approval for use as a post-exposure preventative measure. This clearance expands the therapeutic landscape for managing SARS-CoV-2 infections.

Childhood Vaccine Schedule: HHS/CDC 2026 Shift

A new executive order from the Trump administration aims to overhaul the childhood vaccine schedule, prompting a review of existing recommendations. This development could significantly impact pharmaceutical companies involved in vaccine development and distribution.

CDER Leadership Changes: Navigating the Impact on Pharmaceutical Strategy

Recent leadership changes within the FDA's Center for Drug Evaluation and Research (CDER) signal potential shifts in regulatory priorities and processes. Understanding these changes is crucial for pharmaceutical companies to adapt their business development and regulatory strategies.

UCB's Bimzelx Triumph: Psoriatic Arthritis Market Implications and Competitive Landscape

UCB's Bimzelx (bimekizumab) has secured significant approvals for psoriatic arthritis, demonstrating strong efficacy in head-to-head trials. This success reshapes the competitive landscape and presents key opportunities and challenges for pharmaceutical business development and investment.

Rusan Pharma Secures PMDA GMP Approval, Boosting Global Market Access

Rusan Pharma has successfully obtained Good Manufacturing Practice (GMP) approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its API and Finished Dosage Formulation (FDF) facilities in Ankleshwar and Dehradun. This significant regulatory milestone strengthens the company's global credentials and opens new avenues for market expansion.

Merck Phase 3 Pipeline: ~80 Trials, Key Gaps

Merck's Phase 3 program reveals significant gaps that could impact its competitive position. This article analyzes the implications for pharma teams and investors.

GlycoNex Secures PMDA Approval for GNX1021 Phase I Trial

GlycoNex has secured approval from Japan's PMDA for the Phase I trial of GNX1021. This regulatory update has important implications for investors and pharmaceutical teams.

MannKind's Pediatric Expansion: A New Era for Afrezza

MannKind's recent approval of Afrezza for pediatric use marks a significant milestone. This article explores the implications for investors and pharma teams.

Rusan Pharma Launches State-of-the-Art API Facility in Pithampur

Rusan Pharma has unveiled a state-of-the-art facility for Active Pharmaceutical Ingredients (APIs) in Pithampur. This development marks a significant milestone in the company's growth strategy.

Biogen Under Investigation: Implications for the Pharma Industry

Biogen faces scrutiny from the Italian regulator regarding market abuse claims related to multiple sclerosis. This article explores the implications for the pharmaceutical industry.

Rusan Pharma Achieves Global GMP Milestone with PMDA Approval

Rusan Pharma has achieved a significant milestone by obtaining PMDA approval, enhancing its global GMP standing. This article explores the implications for stakeholders.

Kelun-Biotech's ASCO 2026 Presentation: Key Insights on NSCLC

Kelun-Biotech is set to present two registrational studies on non-small cell lung cancer at ASCO 2026, highlighting significant regulatory updates and investment implications.

AbbVie and GSK's Rise in Patient Reputation: Insights for Pharma

AbbVie and GSK have made significant strides in patient reputation in the UK. This article explores the implications for the pharmaceutical industry.

Merck's TroFuse-005 Trial Results: Implications for Investors and Pharma Teams

Merck's TroFuse-005 trial evaluating Sacituzumab Tirumotecan has met primary endpoints of overall survival and progression-free survival in advanced endometrial cancer. This article explores the implications for investors and pharmaceutical teams.